Nano-Fe3O4@SiO2/SnCl4 Promoted Synthesis of Indenopyrido[2,3-d] Pyrimidine Derivatives in Water

Document Type : Research Paper

Authors

1 Department of Chemistry, College of Science, Yazd University, Yazd,

2 Department of Chemistry, College of Science, Yazd University, Yazd

3 yazd universiy

4 Department of Organic Chemistry, Faculty of Chemistry, University of Kashan, Kashan, Iran

10.22052/JNS.2024.03.024

Abstract

Pyrido[2,3-d]pyrimidine derivatives show variable biological activities such as anticancer, antitumor, antiviral, antihistaminic, anti-inflammatory and antibacterial. In this work, an efficient and environment friendly method for one-pot synthesis of indenopyrido[2,3-d]pyrimidine derivatives was developed in the presence of nano-Fe3O4@SiO2/SnCl4 nanoparticles in water. Indenopyrido[2,3-d]pyrimidines were synthesized via three-component couplings of 6-amino-2-(methylthio)pyrimidin-4(3H)-one, aldehydes and 1,3-indanedione under heating or ultrasound irradiation conditions in water. The structure of the obtained products was approved by FT-IR, 1H NMR and 13C NMR techniques. The mild reaction conditions, green and cost-effective catalyst, excellent yields, and easy work-up procedures, which avoid the use of large volumes of hazardous organic solvents, make it a useful protocol.

Keywords

Full Text

INTRODUCTION
Pyridopyrimidines are nitrogen-bearing heterocyclic compounds which have various pharmaceutical applications. In particular, pyrido[2,3-d]pyrimidine derivatives show variable biological activities such as anticancer agents inhibiting dihydrofolate reductases or tyrosine kinases [1], antitumor [2], antiviral [3], antihistaminic [4], anti-inflammatory  [5], antibacterial [6], and also act as cyclin-dependent kinase 4 inhibitors [7]. This structural moiety is present in ramastine (anti-allergic) [8] and pirenperone (tranquilizer) [9]. As a result, the compounds of this class have attracted considerable interest for research. Several MCR methods have been reported for the synthesis of pyrido[2,3-d]pyrimidines [10]. Although most of these methods offer distinct advantages, some of them still have their own limitations in terms of yields, longer reaction times and difficult work-ups. In some cases, the used catalysts are harmful to the environment and cannot be reused. Therefore, an efficient method for the preparation of pyrido[2,3-d]pyrimidine derivatives is still desirable. In this work, we wish to report an efficient and eco-friendly procedure for the preparation of indenopyrido[2,3-d]pyrimidine in the presence of nano-Fe3O4@SiO2/SnCl4 [11,12]. 

MATERIALS AND METHODS
Materials and apparatus
Chemicals and solvents were purchased from Merck and Aldrich Companies. FT-IR spectra were recorded as KBr pellet on a Bruker, Equinox 55 spectrometer. 1H NMR and 13C NMR spectra were recorded on a 400 MHz Bruker DRX-400 in DMSO-d6 as solvent and TMS as an internal standard. Melting points were obtained with a Buchi melting point B-540 B.V.CHI apparatus. Ultrasonic irradiations were done using Elmasonic S 40H ultrasonic cleaning.

General procedure for the synthesis of indenopyrido[2,3-d]pyrimidines
A mixture of 6-amino-2-(alkylthio) pyrimidin-4(3H)-one (1 mmol), 1, 3-indanedione (1 mmol), aldehydes (1 mmol), nano-Fe3O4@SiO2/SnCl4 (0.03 g) and 8 ml of water was heated under reflux or ultrasonic cleaning unit at 70 ºC. The progress of the reaction was monitored by TLC (EtOAc: petroleum ether, 7:3). After completion of the reaction, the catalyst was separated by an external magnet and reused for the next experiment. The reaction mixture was cooled to room temperature and then poured in to cold water. The solid product was filtered and washed with boiling water and recrystallized from ethanol to give the pure product in excellent yield.

Spectral data for selected compounds
5-(4-Chlorophenyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6(5H, 11H)-dione (4a).
Red Powder; M.P. >300 °C; FT-IR (KBr, ῡ, cm−1): 3251, 3126, 3037, 2926, 1646, 1543, 1498, 1452, 1355, 1274, 1185, 1086, 902, 834, 746, 713; 1H NMR (ppm): δ 2.60 (s, 3H, CH3), 4.82 (s, 1H, CH), 7.30–7.25 (m, 5H, Ar-H), 7.36 (t, 1H, J = 7.40 Hz, Ar-H), 7.45 (t, 1H, J = 7.40 Hz, Ar-H), 7.79 (d, 1H, J = 7.20 Hz, Ar-H), 11.13 (brs, 1H, NH), 12.60 (brs, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 34.2 (CH), 99.9, 107.9, 120.4, 120.9, 128.4, 130.1, 130.8, 131.2, 132.4, 133.6, 136.6, 137.5, 144.8, 153.5, 155.8, 161.5 (CONH), 191.1 (C=O).

5-(4-Bromophenyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6(5H, 11H)-dione (4b).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3220, 3125, 3032, 2926, 1644, 1543, 1497, 1450, 1353, 1272, 1185, 1074, 966, 901, 834, 711; 1H NMR (ppm): δ 2.60 (s, 3H, CH3), 4.80 (s, 1H, CH), 7.21 (d, 2H, J = 7.60 Hz, Ar-H), 7.26 (d, 1H, J = 6.80 Hz, Ar-H), 7.35 (t, 1H, J = 7.20 Hz, Ar-H), 7.42 (m, 3H, Ar-H), 7.79 (d, 1H, J = 6.80 Hz, Ar-H), 11.12 (br s, 1H, NH), 12.58 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 34.3 (CH), 99.9, 107.8, 119.7, 120.4, 120.9, 129.6, 130.5, 130.8, 131.3, 132.4, 133.6, 136.6, 145.2, 155.8, 162.1 (CONH), 191.1 (C=O).

5-(4-Fluorophenyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6(5H, 11H)-dione (4c).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3117, 3026, 2923, 2850, 1644, 1542, 1499, 1455, 1358, 1276, 1225, 1187, 962, 902, 842, 711; 1H NMR (ppm): δ 2.60 (s, 3H, CH3), 4.83 (s, 1H, CH), 7.07–7.01 (m, 4H, Ar-H), 7.26 (d, 2H, J = 6.40 Hz, Ar-H), 7.35 (t, 1H, J = 7.40 Hz, Ar-H), 7.45 (t, 1H, J = 7.20 Hz, Ar-H), 7.79 (d, 1H, J = 7.20 Hz, Ar-H), 11.10 (br s, 1H, NH), 12.56 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 34.0 (CH), 99.6, 108.1, 114.9 (d, 2𝐽C-F = 21.0 Hz), 120.3, 120.7, 129.9 (d, 3𝐽C-F = 8.0 Hz), 130.6, 132.1, 133.9, 136.8, 142.6, 153.3, 156.1, 158.9, 160.6 (d, 1𝐽C-F = 240.0 Hz), 191.0 (C=O).

5-(2-Bromophenyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6(5H, 11H)-dione (4d).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3230, 3123, 3048, 2936, 2849, 1645, 1549, 1499, 1455, 1349, 1273, 1188, 1038, 963, 890, 768, 712; 1H NMR (ppm): δ 2.60 (s, 3H, CH3), 5.24 (s, 1H, CH), 7.06 (dt, 1H, J = 8.40 Hz, 2.20 Hz, Ar-H), 7.28–7.21 (m, 3H, Ar-H), 7.35 (t, 1H, J = 7.40 Hz, Ar-H), 7.48–7.43 (m, 2H, Ar-H), 7.80 (d, 1H, J = 7.20 Hz, Ar-H), 11.11 (br s, 1H, NH), 12.26 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 35.7 (CH), 100.0, 107.8, 120.4, 120.7, 123.4, 128.1, 128.4, 130.7, 132.0, 132.2, 132.8, 133.6, 136.6, 136.7, 144.9, 153.7, 155.6, 162.1 (CONH), 190.7 (C=O). 

5-(2-Chlorophenyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6(5H, 11H)-dione (4e).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3238, 3142, 3067, 2975, 2924, 2851, 1648, 1544, 1491, 1440, 1349, 1265, 1186, 1043, 961, 900, 825, 757; 1H NMR (ppm): δ 2.60 (s, 3H, CH3), 5.24 (s, 1H, CH), 7.15 (d, 1H, J = 7.20 Hz, Ar-H), 7.21 (t, 2H, J = 7.40 Hz, Ar-H), 7.29 (d, 2H, J = 7.20 Hz,Ar-H), 7.35 (t, 1H, J = 7.20 Hz, Ar-H), 7.44 (t, 1H, J = 7.20 Hz, Ar-H), 7.79 (d, 1H, J = 7.20 Hz, Ar-H), 11.10 (br s, 1H, NH), 12.49 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 33.3 (CH), 99.9, 107.6, 120.4, 120.7, 127.4, 128.1, 129.5, 130.7, 131.9, 132.2, 132.9, 133.6, 136.6, 143.1, 153.7, 155.9, 162.1 (CONH), 190.7 (C=O). 

5-(2,4-Dichlorophenyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6(5H, 11H)-dione (4g).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3432, 3149, 3068, 2928, 1650, 1548, 1502, 1452, 1352, 1274, 1188, 1050, 967, 901, 856, 763, 706; 1H NMR (ppm): δ 2.60 (s, 3H, CH3), 5.22 (s, 1H, CH), 7.23 (d, 1H, J = 6.40 Hz, Ar-H), 7.37–7.27 (m, 3H, Ar-H), 7.47–7.44 (m, 2H, Ar-H), 7.80 (d, 1H, J = 7.20 Hz, Ar-H), 11.13 (br s, 1H, NH), 12.52 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 33.0 (CH), 99.4, 107.1, 120.5, 120.7, 127.6, 128.7, 130.8, 131.7, 132.2, 133.0, 133.5, 133.9, 142.3, 136.6, 153.8, 156.0, 162.0 (CONH), 190.7 (C=O).

5-(2-Hydroxyphenyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6(5H, 11H)-dione (4h).
Orang Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3377, 3131, 3068, 2931, 1694, 1646, 1619, 1556, 1500, 1443, 1405, 1353, 1277, 1223, 1193, 970, 899, 763, 711; 1H NMR (ppm): δ 2.59 (s, 3H, CH3), 4.98 (s, 1H, CH), 6.72–6.69 (m, 2H, Ar-H), 7.03–7.0 (m, 2H, Ar-H), 7.25 (d, 1H, J = 6.80 Hz, Ar-H), 7.35 (t, 1H, J = 7.40 Hz, Ar-H), 7.45 (t, 1H, J = 7.40 Hz, Ar-H), 7.79 (d, 1H, J = 7.20 Hz, Ar-H), 9.58 (br s, 1H, NH), 11.12 (s, 1H, OH), 12.73 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 29.6 (CH), 100.0, 107.9, 117.5, 120.0, 120.2, 120.8, 127.9, 130.0, 130.6, 132.3, 133.8, 136.8, 136.9, 154.8, 155.0, 156.4, 156.5, 163.9 (CONH), 191.1 (C=O).

5-Phenyl-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6(5H,11H)-dione (4i).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3433, 3024, 2922, 2848, 1719, 1647, 1541, 1497, 1453, 1357, 1275, 1189, 966, 902, 744, 701; 1H NMR (ppm): δ 2.60 (s, 3H, CH3), 4.82 (s, 1H, CH), 7.15–7.11 (m, 1H, Ar-H), 7.26–7.21 (m, 4H, Ar-H), 7.34 (t, 2H, J = 7.40 Hz, Ar-H), 7.44 (t, 1H, J = 7.60 Hz, Ar-H), 7.78 (d, 1H, J = 7.20 Hz, Ar-H), 11.07 (br s, 1H, NH), 12.55 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 34.5 (CH), 100.0, 108.5, 120.3, 120.8, 126.6, 127.4, 128.2, 128.5, 130.6, 132.3, 133.7, 136.7, 146.0, 153.3, 155.7, 162.5 (CONH), 191.1 (C=O). 

5-(p-Tolyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6 (5H,11H)-dione (4j).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1):  3490, 3227, 3126, 3027, 2925, 1647, 1539, 1545, 1499, 1450, 1355, 1272, 1186, 963, 788, 710; 1H NMR (ppm): δ 2.21 (s, 3H, CH3), 2.59 (s, 3H, CH3), 4.77 (s, 1H, CH), 7.03 (d, 2H, J = 7.20 Hz,Ar-H), 7.12 (d, 2H, J = 7.20 Hz, Ar-H), 7.25 (d, 1H, J = 6.40 Hz, Ar-H), 7.34 (t, 1H, J = 7.20 Hz, Ar-H), 7.44 (t, 1H, J = 7.20 Hz, Ar-H), 7.77 (d, 1H, J = 6.80 Hz, Ar-H), 11.04 (br s, 1H, NH), 12.54 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 21.0 (Me), 34.1 (CH), 100.2, 108.7, 120.2, 120.8, 128.0, 128.4, 129.0, 130.6, 132.3, 133.7, 135.6, 136.8, 143.1, 153.2, 155.5, 162.4 (CONH), 191.1 (C=O).

5-(4-Methoxyphenyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6(5H, 11H)-dione (4k).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3212, 2920, 2853, 1675, 1639, 1605, 1551, 1489, 1437, 1349, 1262, 1218, 1187, 1146, 1020, 967, 901, 837, 768, 704; 1H NMR (ppm): δ 2.59 (s, 3H, CH3), 3.68 (s, 3H, OCH3), 4.76 (s, 1H, CH), 6.79 (d, 2H, J = 8.20 Hz, Ar-H), 7.14 (d, 2H, J = 8.20 Hz, Ar-H), 7.26 (d, 1H, J = 7.20 Hz, Ar-H), 7.35 (t, 1H, J = 7.20 Hz,Ar-H), 7.44 (t, 1H, J = 7.40 Hz, Ar-H), 7.78 (d, 1H, J = 6.80 Hz, Ar-H), 11.03 (br s, 1H, NH), 12.53 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 33.6 (CH), 55.4 (MeO), 95.0, 108.7, 112.8, 113.9, 120.2, 120.8, 129.1, 130.6, 132.3, 133.7, 136.8, 138.2, 155.4, 158.1, 161.5 (CONH), 191.2 (C=O).

5-(3,4-Dimethoxyphenyl)-2-(methylthio)-3H-indeno[5,6:1´,2´]pyrido[2,3-d]pyrimidine-4,6 (5H,11H)-dione (4l).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3390, 3233, 3141, 3063, 2933, 2845, 1656, 1602, 1553, 1505, 1451, 1345, 1268, 1180, 1140, 1025, 963, 899, 766, 712; 1H NMR (ppm): δ 2.60 (s, 3H, SCH3), 3.67 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 4.79 (s, 1H, CH), 6.64 (d, 1H, J = 8.40 Hz, Ar-H), 6.74 (d, 1H, J = 8.40Hz, Ar-H), 6.95 (s, 1H, Ar-H), 7.27 (d, 1H, J = 6.80 Hz, Ar-H), 7.34 (t, 1H, J = 7.20 Hz, Ar-H), 7.43 (t, 1H, J = 7.20 Hz, Ar-H), 7.77 (d, 1H, J = 7.20 Hz, Ar-H), 11.01 (br s, 1H, NH), 12.54 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 33.9 (CH), 55.9 (MeO), 56.0 (MeO), 100, 108.5, 112.3, 112.6, 119.8, 120.2, 120.8, 130.6, 132.3, 133.7, 136.7, 138.6, 147.8, 148.6, 155.4, 162.5 (CONH), 191.2 (C=O).

5-(4-Hydroxy-3-methoxyphenyl)-2-(methylthio)-3H-indeno[2’,1’:5,6]pyrido[2,3-d]pyrimidine -4,6(5H,11H)-dione (4m).
Red Powder; M.p.: >300 °C; FT-IR (KBr, ῡ, cm−1): 3341, 3067, 2924, 2843, 1690, 1651, 1567, 1505, 1453, 1340, 1273, 1243, 1219, 1170, 1149, 1040, 956, 898, 792, 709; 1H NMR (ppm): δ 2.60 (s, 3H, SCH3), 3.72 (s, 3H, OCH3), 4.74 (s, 1H, CH), 6.51 (d, 1H, J = 8.0 Hz, Ar-H), 6.63 (d, 1H, J = 8. 0 Hz, Ar-H), 6.91 (s, 1H, Ar-H), 7.27 (d, 1H, J = 7.20 Hz, Ar-H), 7.35 (t, 1H, J = 7.40 Hz, Ar-H), 7.44 (t, 1H, J = 7.20 Hz, Ar-H), 7.77 (d, 1H, J = 7.20 Hz, Ar-H), 8.76 (s, 1H, OH), 11.01 (br s, 1H, NH), 12.55 (br s, 1H, CO–NH); 13C NMR (ppm): 𝛿 13.3 (Me), 33.8 (CH), 56.1 (MeO), 100, 108.7, 112.9, 115.6, 120.0, 120.2, 120.8, 130.6, 132.3, 133.7, 136.8, 137.1, 145.5, 147.4, 155.4, 162.1 (CONH), 191.3 (C=O).

RESULTS AND DISCUSSION
Following our continued studies in the development of benign methods [11-20], we have examined the synthesis of indenopyrido[2,3-d]pyrimidine in the presence of nano-Fe3O4@SiO2/SnCl4. For this purpose, multi-component condensation reactions of 6-amino-2-(methylthio)pyrimidin-4(3H)-one, aryl aldehydes and 1, 3-indanedione were done. 
To optimize the desired reaction conditions, the preparation of 5-(4-chlorophenyl)-2-(methylthio)-3H-indeno[2,1:5,6]pyrido[2,3-d]pyrimidine-4,6-(5H,11H)-dione (4a) was selected as the model reaction. In initial experiments, the effects of solvents and reaction temperature were evaluated for this model reaction in the presence of nano-Fe3O4@SiO2/SnCl4, and results are summarized in tables 1. It is evident from the results that using nano-Fe3O4@SiO2/SnCl4 as catalyst in water at 70 °C is the most effective condition producing the higher yield product (4a, 90%) in lower reaction time (Table 1, Entry 4).
Using the best obtained reaction condition, we have also established the amount of the catalyst required for the model reaction in water (Table 2). The obtained results showed that, in the absence of a catalyst, no significant product was obtained, and in the presence of nano-Fe3O4@SiO2/SnCl4, the reaction was carried out with high yields. For example, the synthesis of a model compound under ultrasound irradiation in the presence of 0.01 g nano-Fe3O4@SiO2/SnCl4 per 1 mmol of any substrate produced a high yield (90%) of product in H2O at 70 ºC after 4 min. Increasing the amount of catalyst to 0.02 g and 0.03 g resulted in increasing the yield to 94% and 98% after 3 and 2 min respectively. Therefore, the best result was obtained using 0.03 g nano-Fe3O4@SiO2/SnCl4 and 1 mmol of any substrate. Notably, the increase of the catalyst in reflux and ultrasound irradiation conditions did not show any significant changes in yield or time of reaction (Entry 9, Table 2).
Using the optimal conditions described in this report, several derivatives of indenopyrido[2,3-d]pyrimidines (4a–m) were prepared in high yields (94–99 %) and short reaction times (1.5–3 min) (Fig. 1 and Table 3).
No obvious effect of the electronic nature of the substituent in the aromatic aldehydes ring was observed. Aromatic aldehydes containing electron-donating groups (such as methoxy and methyl groups) or electron-withdrawing groups (such as halides and nitro groups) were employed and reacted to give the corresponding products 4a–m in high yield under the optimized reaction conditions. The structure of all products was established by spectroscopic methods (IR, 1H NMR and 13C NMR).
In all cases, when the reactions were carried out under ultrasound irradiation, the times of the reactions were shorter and the yields of the products were higher than with the heating method. 
A proposed mechanism for the synthesis of indenopyrido[2,3-d]pyrimidines in the presence of Fe3O4@SiO2-SnCl4, as a Lewis acid catalyst is shown in scheme 2. The carbonyl oxygen of aldehyde coordinates with the Lewis acid moiety, increasing the electrophilicity of the carbonyl group and thereby making it possible to carry out the reaction in a short time. In a plausible mechanism, it is assumed that the reaction may proceed initially through the Knoevenagel condensation between arylaldehydes and 1, 3-indanedione to form intermediate (I). Next, michael addition of 6-amino-2-(methylthio)-pyrimidin-4(3H)-one to intermediate (I) affords (II). Intermediate (II) converts to (III) after tautomerization. Then, Intermediate (III) converts to intermediate (IV) via cyclization. Finally, the desired product (V) is obtained after tautomerization of (IV) (Fig. 2).
Consequently, it is essential for the solid acid to maintain strong acidity even after recycling, which has the most important benefits for commercial applications. The catalyst was also recycled and reused in the preparation of 4a as a model compound. After completion of the reaction, nano-Fe3O4@SiO2/SnCl4 is easily separated by an external magnet. The recovered catalyst was washed with ethanol (15 mL) and dried at room temperature without further purification for use in the next run in the current reaction under identical conditions. The result showed that after five successive runs, catalytic activity of the catalyst was retained without significant loss of activity (Fig. 3).

CONCLUSION
In summary, for the first time, we have shown that nano-Fe3O4@SiO2/SnCl4 was an effective heterogeneous catalyst for the one-pot synthesis of indenopyrido[2,3-d]pyrimidine derivatives from 6-amino-2-(methylthio)-pyrimidin-4(3H)-one, aryl aldehyde and 1,3-indanedione under reflux and ultrasound irradiation conditions in water. The mild reaction conditions, green and cost-effective catalyst, excellent yields, and easy work-up procedures, which avoid the use of large volumes of hazardous organic solvents, make it a useful alternative to previously reported procedures. Compared with a nonmagnetic nanoparticle catalytic system, the present protocol combines the advantages of solid Lewis acid and magnetic nanoparticles and offers great potential for the rapid synthesis of indenopyrido[2,3-d]pyrimidine derivatives.

ACKNOWLEDGEMENTS
The authors are grateful to the Research Council of Yazd University for financial support of this work.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interests regarding the publication of this manuscript.

 

References

1.    Gangjee A, Adair O, Queener SF. Pneumocystis carinii and Toxoplasma ondii Dihydrofolate Reductase Inhibitors and Antitumor Agents:  Synthesis and Biological Activities of 2,4-Diamino-5-methyl-6-[(monosubstituted anilino)methyl]- pyrido[2,3-d]pyrimidines. J Med Chem. 1999;42(13):2447-2455.
2.    Broom AD, Shim JL, Anderson GL. Pyrido[2,3-d]pyrimidines. IV. Synthetic studies leading to various oxopyrido[2,3-d]pyrimidines. The Journal of Organic Chemistry. 1976;41(7):1095-1099.
3.    Wiegrebe W. Antibiotics and Antiviral Compounds, Herausgeber K. Krohn, H.A. Kirst, H. Maag, VCH, XVI, 482 S, Weinheim,1993, DM 128,—. Arch Pharm. 1994;327(3):199-199.
4.    Quintela J, Peinador C, Botana L, Estévez M, Riguera R. Synthesis and antihistaminic activity of 2-guanadino-3-cyanopyridines and pyrido[2,3-d]-pyrimidines. Bioorganic and Medicinal Chemistry. 1997;5(8):1543-1553.
5.    El-Gazzar A-RBA, Hafez HN. Synthesis of 4-substituted pyrido[2,3-d]pyrimidin-4(1H)-one as analgesic and anti-inflammatory agents. Bioorganic and Medicinal Chemistry Letters. 2009;19(13):3392-3397.
6.    DeGraw JI, Kisliuk RL, Gaumont Y, Baugh CM. Antimicrobial activity of 8-deazafolic acid. J Med Chem. 1974;17(4):470-471.
7.    VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J, et al. Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4. J Med Chem. 2005;48(7):2371-2387.
8.    Awouters F, Vermeire J, Smeyers F, Vermote P, van Beek R, Niemegeers CJE. Oral antiallergic activity in ascaris hypersensitive dogs: A study of known antihistamines and of the new compounds ramastine (R 57 959) and levocabastine (R 50 547). Drug Dev Res. 1986;8(1-4):95-102.
9.    Smith RL, Gresch PJ, Barrett RJ, Sanders-Bush E. Stimulus generalization by fenfluramine in a quipazine–ketanserin drug discrimination is not dependent on indirect serotonin release. Pharmacol Biochem Behav. 2002;72(1-2):77-85.
10.    Bazgir A, Khanaposhtani MM, Ghahremanzadeh R, Soorki AA. A clean, three-component and one-pot cyclo-condensation to pyrimidine-fused heterocycles. Comptes Rendus Chimie. 2009;12(12):1287-1295.
11.    Bamoniri A, Fouladgar S. SnCl4-functionalized nano-Fe3O4 encapsulated-silica particles as a novel heterogeneous solid acid for the synthesis of 1,4-dihydropyridine derivatives. RSC Advances. 2015;5(96):78483-78490.
12.    Bamoniri A, Mirjalili BBF, Fouladgar S. Fe3O4@SiO2-SnCl4: An Efficient Catalyst for the Synthesis of Xanthene Derivatives under Ultrasonic Irradiation. Polycyclic Aromatic Compounds. 2016;37(5):345-361.
13.    Akrami H, Mirjalili BF, Khoobi M, Moradi A, Nadri H, Emami S, et al. ChemInform Abstract: 9H‐Carbazole Derivatives Containing the N‐Benzyl‐1,2,3‐triazole Moiety as New Acetylcholinesterase Inhibitors. ChemInform. 2015;46(37).
14.    Akrami H, Mirjalili BF, Khoobi M, Nadri H, Moradi A, Sakhteman A, et al. Indolinone-based acetylcholinesterase inhibitors: Synthesis, biological activity and molecular modeling. Eur J Med Chem. 2014;84:375-381.
15.    Mirjalili BF, Zamani L, Zomorodian K, Khabnadideh S, Haghighijoo Z, Malakotikhah Z, et al. Synthesis, antifungal activity and docking study of 2-amino-4H-benzochromene-3-carbonitrile derivatives. J Mol Struct. 2016;1116:102-108.
16.    Zamani L, Mirjalili BBF. Synthesis and characterization of tetraarylporphyrins in the presence of nano-TiCl4·SiO2. Chemistry of Heterocyclic Compounds. 2015;51(6):578-581.
17.    Zamani L, Zomorodian K, Mirjalili BBF, Khabnadideh S. One pot preparations 1-amidoalkyl-2-naphthols derivative catalyzed by nano-TiCl4.SiO2 with antimicrobial studies of some products. Journal of Pharmaceutical and Scientific Innovation. 2014;3(3):208-216.
18.    Azad S, Fatameh Mirjalili BB. Fe3O4@nano-cellulose/TiCl: a bio-based and magnetically recoverable nano-catalyst for the synthesis of pyrimido[2,1-b]benzothiazole derivatives. RSC Advances. 2016;6(99):96928-96934.
19.    Bamoniri A, Moshtael-Arani N. Nano- Fe3O4 encapsulated-silica supported boron trifluoride as a novel heterogeneous solid acid for solvent-free synthesis of arylazo-1-naphthol derivatives. RSC Advances. 2015;5(22):16911-16920.
20.    Mirjalili BBF, Bamoniri A, Azad S. Synthesis of 2,3-dihydroquinazolin-4(1H)-ones catalyzed by nano- Fe3O4/TiCl2/cellulose as a bio-based magnetic catalyst. Journal of the Iranian Chemical Society. 2016;14(1):47-55.
21.    Mirjalili BBF, Dehghani Tafti M. Nano-kaoline/BF3/Fe3O4 Eco-friendly Nano-catalyst Promoted Synthesis of Quinoxalines Under Grinding Condition. Sci Iranica. 2017;0(0):0-0.
Journal of Nanostructures
Volume 14, Issue 3
July 2024
Pages 963-970

Files

Share

How to cite

Statistics